A new online tool that could better predict the long-term risk of breast cancer returning in other areas of the body has been created.
The prognostic tool, known as CTS5 (Clinical Treatment Score post-5-years), could be used to decide which patients are at high enough risk of their cancer returning after receiving the standard five years of endocrine (hormone) therapy, and could therefore benefit from continuation of treatment.
The simple web-based calculator was developed by researchers at the Royal Marsden NHS Foundation Trust and Queen Mary, University of London, who said it could also be used to predict which patients are at low risk of recurrence.
This means they can avoid undergoing further therapy and its potential adverse side effects.
Researchers said that over the last three decades there has been a major increase in the rate of invasive breast cancer in western countries.
About 85% of patients are now diagnosed as oestrogen receptor (ER) positive, which means that the cancer grows in response to the hormone oestrogen.
Almost all of these patients are prescribed five years of hormone therapy after having standard treatment (surgery, chemotherapy, and/or radiation therapy), to lower the risk of the cancer returning.
However, hormone therapy can have significant side effects, including weakness of bone tissue and exacerbation of menopausal symptoms.
Oncologists, along with patients, have to decide after five years of hormone treatment whether extending this type of therapy is worthwhile and appropriate.
The team developed CTS5 after reviewing data from two previously published studies.
Together these provided information on 11,446 postmenopausal women with ER positive breast cancer who had received five years of hormone therapy (tamoxifen, anastrozole, or letrozole).
CTS5 was shown to be able to accurately separate women into groups of low, intermediate, or high risk of developing a late distant recurrence breast cancer after five years of hormone therapy.
The test identified 42% of women as who were sufficiently low risk so that extending hormone therapy would have been of very little value.
Co-lead researcher Mitch Dowsett, head of the Royal Marsden Ralph Lauren Centre for Breast Cancer Research and professor of biochemical endocrinology at the Institute of Cancer Research (ICR), said the calculator could improve clinical practice and benefit breast cancer patients by them avoiding potentially unnecessary extended treatment.
Prof Dowsett added: “Clinicians require expertise and the best tools to help them make crucial decisions on treatment for patients, decisions that can make a difference to patients’ quality of life.
“This tool uses information that is already gathered in all patients, so could be easily used across the UK and globally at other centres.”
Co-lead researcher Professor Jack Cuzick, from Queen Mary, University of London, said: “Hormone sensitive breast cancer is one of the few cancers where late recurrence is common, and predicting who is at high risk is particularly important so that they can continue hormone treatment.
“While our ability to predict this type of cancer is highly likely to improve in the future, we’re providing a simple tool which is available now, and is easily used and well tested.”
Details have been published in the Journal of Clinical Oncology.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here